# Divesiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/divesiran

> The next catalyst for divesiran, sponsored by Silence Therapeutics plc (SLN), is its trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for divesiran?

The next catalyst for divesiran, sponsored by Silence Therapeutics plc (SLN), is its trial start, 1H 2027. SEC Form 8-K: "Based on the Phase 2 results, the Company expects to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/divesiran)

Source: SEC Form 8-K, accession 0001193125-26-341293, https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm (retrieved 2026-11-12). Last confirmed 2026-08-12. Cite: https://sec-api.dev/pdufa/divesiran#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | divesiran |
| Codes | SLN124 |
| Sponsor | Silence Therapeutics plc (SLN) https://sec-api.dev/companies/sln/catalysts |
| Indications |  |
| Modality | sirna |
| FDA designations | fast track, orphan |

## Timeline

### Jun 2024: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 1.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126791): "In June 2024, we reported positive interim results from the Phase 1 portion of the SANRECO trial." https://www.sec.gov/Archives/edgar/data/1479615/000095017024126791/sln-ex99_1.htm

### Dec 2024: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 1.
- First seen 2025-02-27, last confirmed 2025-05-08.
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO Phase 1/2 clinical trial of divesiran in PV patients at the 66th American Society of Hematology (ASH) Annual Meeting." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we presented positive interim results from the Phase 1 Portion of the SANRECO Phase 1/2 clinical trial of divesiran in 19 PV patients at the 66th ASH Annual Meeting." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm
- SEC Form 10-Q (accession 0000950170-25-066439): "In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO clinical trial at the American Society of Hematology annual meeting." https://www.sec.gov/Archives/edgar/data/1479615/000095017025066439/sln-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO clinical trial at the American Society of Hematology (ASH) annual meeting." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO clinical trial at the American Society of Hematology, or ASH, annual meeting." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm

### December 9, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2024-12-09, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-272929): "Silence also announces first subject dosed in Phase 2 study of divesiran in PV patients" https://www.sec.gov/Archives/edgar/data/1479615/000119312524272929/d911238dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-272929): "Silence also announced today the first subject has been dosed in the Phase 2 portion of the SANRECO Study." https://www.sec.gov/Archives/edgar/data/1479615/000119312524272929/d911238dex991.htm
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we announced the first subject has been dosed in the Phase 2 randomized, double-blind portion of the SANRECO clinical trial of divesiran in PV patients." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm
- SEC Form 10-Q (accession 0000950170-25-066439): "In December 2024, we also announced the first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial, which is currently underway." https://www.sec.gov/Archives/edgar/data/1479615/000095017025066439/sln-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we also announced the first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial which is currently underway." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm
- SEC Form 10-K (accession 0000950170-25-029129): "In December 2024, we also announced that the first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial which is currently underway." https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm

### Q3 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-10-23, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-247692): "Initial topline results from the SANRECO Phase 2 study are anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/sln-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268102): "Following accelerated completion of Phase 2 enrollment, initial topline results from SANRECO are anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-268116): "The ongoing SANRECO Phase 2 clinical trial is fully enrolled, and we anticipate the announcement of initial topline results from the trial in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312525268116/sln-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-247692): "Initial topline results are anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/sln-ex99_1.htm

### August 10, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-11-06, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457060): "On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy silencing TMPRSS6, in polycythemia vera, supporting a potentially best-in-class profile with once-every-three-month dosing." https://www.sec.gov/Archives/edgar/data/1479615/000119312526457060/d101909dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341293): "Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV)." https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947dex991.htm
- SEC prospectus (424B) (accession 0001193125-26-347191): "On August 10, 2026, we announced positive topline results from the Phase 2 SANRECO trial, a 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously every six weeks ("Q6W") or every twelve weeks ("Q12W") met its primary endpoint and secondary endpoints." https://www.sec.gov/Archives/edgar/data/1479615/000119312526347191/d149256d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-342633): "On August 10, 2026, we announced positive topline results from the Phase 2 SANRECO trial, a 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously every six weeks ("Q6W") or every twelve weeks ("Q12W") met its primary endpoint and secondary endpoints." https://www.sec.gov/Archives/edgar/data/1479615/000119312526342633/d149256d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-458896): "In August 2026, we announced positive topline results from the Phase 2 SANRECO study evaluating divesiran in 48 phlebotomy-dependent PV patients." https://www.sec.gov/Archives/edgar/data/1479615/000119312526458896/sln-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268102): "SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026" https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-266705): "These findings further support the potential for less frequent dosing, including the Q12W regimen being evaluated in our ongoing Phase 2 SANRECO study, and we look forward to reporting topline results in August 2026."" https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/sln-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-092591): "Accelerated timing for topline results in the Phase 2 SANRECO trial of divesiran, a potential first-in-class siRNA for PV; now anticipated in the third quarter of 2026, as opposed to our prior guidance of the second half of 2026 due to faster than expected enrollment." https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm
- SEC Form 10-Q (accession 0001193125-26-341248): "The SANRECO Phase 2 trial completed patient dosing in June 2026 and topline results are anticipated in August 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312526341248/sln-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-210446): "The SANRECO Phase 2 trial is fully enrolled and topline results are anticipated in August 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312526210446/sln-20260331.htm
- SEC Form 10-K (accession 0001193125-26-092591): "The SANRECO Phase 2 trial is fully enrolled, and topline results are anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm
- SEC Form 10-K (accession 0001193125-26-092591): "The SANRECO Phase 2 trial is fully enrolled and topline results are anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-08-10, last confirmed 2026-08-12.
- SEC Form 8-K (accession 0001193125-26-341293): "Based on the Phase 2 results, the Company expects to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm
- SEC prospectus (424B) (accession 0001193125-26-347191): "Based on the Phase 2 results, we expect to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1479615/000119312526347191/d149256d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-342633): "Based on the Phase 2 results, we expect to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1479615/000119312526342633/d149256d424b5.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/divesiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Divesiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/divesiran

```bibtex
@misc{secapidev_pdufa_divesiran_20261116,
  title        = {Divesiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/divesiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_divesiran_20261116","title":"Divesiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/divesiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
